DRKS00028745招募中不适用
Immune cell score and therapeutic response to checkpoint inhibitors in patients with advanced lung cancer
niversitätsmedizin Göttingen0 个研究点目标入组 700 人开始时间: 2022年6月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Metastatic lung cancer, therapy with at least one checkpoint inhibitor as monotherapy or in combination with chemotherapy
排除标准
- •Therapy in the context of other clinical studies in which the administered active substance is unclear
研究者
相似试验
招募中
Unknown
Evaluation of treatment response for immune checkpoint inhibitors in non-small cell lung cancer patients using [18F]F-AraG PET/CTlung cancerJPRN-jRCTs051220109akamoto Yuji60
招募中
Unknown
Prognostic Predictors for the efficacy of Immune Checkpoint InhibitorsThoracic cancerJPRN-UMIN000053613Juntendo University Urayasu Hospital250
招募中
1 期
Immune cell therapy for pediatric patients with brain tumor.Malignant brain tumorJPRN-jRCTc030200051Kondo Akihide3
进行中（未招募）
1 期
Comparison of the immunogenicity and safety of a combined adsorbed low dose diphtheria, tetanus and inactivated poliomyelitis vaccine (REVAXIS®) with a combined diphtheria, tetanus and inactivated poliomyelitis vaccine (DT Polio®) when given as a booster dose at 6 years of age - REVAXIS® versus DT Polio® as a second booster in 6 year-old childreot applicable - Healthy volunteers - 6 year-old childEUCTR2005-001446-16-FRSanofi Pasteur MSD760
已完成
不适用
Evaluation of Immunological Changes in patients treated with CyberKnife® radiosurgery and RadiotherapyCTRI/2011/06/001800Health Care Global Enterprises Ltd100